Intesa invests 360 million euros to manage its entire health insurance business

Published Date: 08 Mar 2023

Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.

Read Full News

Latest News

Federal Agencies Widen Med School Admissions Investigations

Departments of Justice, Education accuse schools of making race-based decisions.

US Senate Panel Advances Trump CDC Pick Schwartz

The U.S. Senate health committee voted on Thursday to advance the nomination of President Donald Trump's pick for CDC director ⁠Dr. Erica Schwartz, handing his...

Doctors Are Asking for Their Lives Back

Physicians aren’t asking for bigger salaries — they’re asking for time and flexibility to enjoy the lives they’ve worked so hard to build.

Where Have All the Leaders Gone? PAs Want to Step Up

Many PAs are well qualified for leadership roles, but organizational barriers and limited opportunities continue to stand in the way.

CMS Proposes Major Medicare Physician Payment Overhaul to Boost Primary Care

The Centers for Medicare & Medicaid Services on Tuesday proposed changes to Medicare's decades-old physician payment system, saying the ⁠updates would support the Trump...

Married to Medicine: The Other Side of the Story

Being married to a doctor isn’t the easiest job. These doctors’ spouses share what it’s like and where to get support.

Todays Updates

Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

A study evaluates whether defibrotide prophylaxis during HSCT reduces the risk for sinusoidal obstruction syndrome in children with relapsed or refractory B-ALL receiving prior inotuzumab.

Todays Updates

Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

A study evaluates whether defibrotide prophylaxis during HSCT reduces the risk for sinusoidal obstruction syndrome in children with relapsed or refractory B-ALL receiving prior inotuzumab.

Latest News

Departments of Justice, Education accuse schools of making race-based decisions.

The U.S. Senate health committee voted on Thursday to advance the nomination of President Donald Trump's pick for CDC director ⁠Dr. Erica Schwartz, handing his...

Physicians aren’t asking for bigger salaries — they’re asking for time and flexibility to enjoy the lives they’ve worked so hard to build.

Many PAs are well qualified for leadership roles, but organizational barriers and limited opportunities continue to stand in the way.

The Centers for Medicare & Medicaid Services on Tuesday proposed changes to Medicare's decades-old physician payment system, saying the ⁠updates would support the Trump...

Being married to a doctor isn’t the easiest job. These doctors’ spouses share what it’s like and where to get support.

News All Time

FDA Grants Emergency Approval for Over-the-counter Drug to Treat Screwworm in Pets

The U.S. Food and Drug Administration on Thursday authorized the emergency use of a generic over-the-counter tablet ⁠to treat infestations caused by the New World screwworm...

More Nurses are Clocking in to Second Jobs

More nurses regularly take on second shifts but as the practice becomes normalized, is this best for patients?

Sandoz Files European Complaint About Chinese Antibiotic Imports

Swiss generic drugmaker Sandoz filed a draft ⁠anti-dumping complaint with the European Commission over Chinese imports ⁠of the antibiotic ingredient amoxicillin.

What Your ZIP Code Is Costing You

Forget salary. The cities winning the physician satisfaction race are playing a completely different game.

How NPs Are Navigating Prior Authorization Coverage Barriers

The same hurdles facing physicians slow treatment for nurse practitioners’ patients, and the impact on care continues.

US FDA Issues Recall Of Boston Scientific Heart Devices

Boston Scientific has issued an urgent recall to correct several heart devices after ⁠the U.S. Food and Drug Administration classified the action as its most serious recall,...

Delays in Visa Program Threaten Hundreds of Doctors

Prolonged HHS J-1 waiver backlogs leave hundreds of foreign-trained doctors facing departure this summer, threatening care in underserved areas, immigration attorneys warn.

AstraZeneca to Invest $405 Million in Britain After US-UK Pharma Deal

Prime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 ⁠million) in the country, after pausing...

Europe Risks Falling Behind in Medicine Race, Roche CEO

Europe risks falling behind the US and China in pharma innovation because of bureaucracy and government policies threatening ⁠jobs, Roche CEO Thomas Schinecker warns.

US Health Regulators to Speed Up Medicare Device Coverage

U.S. health regulators announced a new program to speed up Medicare coverage for certain medical devices on ⁠Thursday, saying it would cut reimbursement timelines to as...

Germany Risks Missing Out on New Drugs, AstraZeneca CEO Says

AstraZeneca's CEO said Germany risks missing out on new drugs that ⁠the drugmaker plans to launch if the nation sticks with plans to keep pharmaceutical spending in check.

U.S. to Ask States to Revalidate "high-risk" Medicaid Providers

Mehmet Oz, who heads the agency that runs the U.S. Medicare and ⁠Medicaid healthcare programs, said on Tuesday the Trump administration plans to ask all ⁠50 states to...

US FDA Warns Medline Over Defective Heart Procedure Syringes

The U.S. Food and Drug Administration has told medical device maker Medline that its syringes used in heart procedures ⁠are defective and warned the company of penal actions.

Swiss Industry Body Says US Tariffs on Pharmaceuticals Will Harm Patients

U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, ⁠supply chains and ultimately will harm patients, Switzerland's...

The ACA Subsidy Gap and Its Toll on Primary Care

When the ACA’s subsidy credits expired at the end of 2025, physicians knew patient volume and overall revenue would tank. How are doctors faring?

Karyopharm's Drug Meets One Of Two Goals in Blood Cancer Trial

Karyopharm Therapeutics said on Tuesday its therapy led to significant reduction in spleen size in a late-stage ⁠study of patients with a rare blood cancer, meeting only one...